Clinical Trial

Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration

Study acronym: Fixed farcimab
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-15; most recent amendment 2025-09-26.
Status change: Not Yet Recruiting → Recruiting 2025-09-26
Trial Details
NCT Number NCT06742307
Lead Sponsor Hospital Authority, Hong Kong
Conditions Macular Degeneration Choroidal Neovascularization
Enrollment 40 participants
Start Date 2025-08-21
Primary Completion 2026-10-01 (estimated)
Study Completion 2027-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-10-01